Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Med Chem
2011 Apr 28;548:2646-57. doi: 10.1021/jm101334y.
Show Gene links
Show Anatomy links
Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
Duque MD, Ma C, Torres E, Wang J, Naesens L, Juárez-Jiménez J, Camps P, Luque FJ, DeGrado WF, Lamb RA, Pinto LH, Vázquez S.
???displayArticle.abstract???
Amantadine inhibits the M2 proton channel of influenza A virus, yet its clinical use has been limited by the rapid emergence of amantadine-resistant virus strains. We have synthesized and characterized a series of polycyclic compounds designed as ring-contracted or ring-expanded analogues of amantadine. Inhibition of the wild-type (wt) M2 channel and the A/M2-S31N and A/M2-V27A mutant ion channels were measured in Xenopus oocytes using two-electrode voltage clamp (TEV) assays. Several bisnoradamantane and noradamantane derivatives inhibited the wt ion channel. The compounds bind to a primary site delineated by Val27, Ala30, and Ser31, though ring expansion restricts the positioning in the binding site. Only the smallest analogue 8 was found to inhibit the S31N mutant ion channel. The structure-activity relationship obtained by TEV assay was confirmed by plaque reduction assays with A/H3N2 influenza virus carrying wt M2 protein.
???displayArticle.pubmedLink???
21466220 ???displayArticle.pmcLink???PMC3174104 ???displayArticle.link???J Med Chem ???displayArticle.grants???[+]
Acharya,
Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus.
2010, Pubmed,
Xenbase
Acharya,
Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus.
2010,
Pubmed
,
Xenbase Aigami,
Biologically active polycycloalkanes. 1. Antiviral adamantane derivatives.
1975,
Pubmed Aldrich,
Antiviral agents. 2. Structure-activity relationships of compounds related to 1-adamantanamine.
1971,
Pubmed Al-Nakib,
Prevention and treatment of experimental influenza A virus infection in volunteers with a new antiviral ICI 130,685.
1986,
Pubmed Balannik,
Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus.
2009,
Pubmed
,
Xenbase Balannik,
Functional studies and modeling of pore-lining residue mutants of the influenza a virus M2 ion channel.
2010,
Pubmed
,
Xenbase Barril,
Virtual screening in structure-based drug discovery.
2004,
Pubmed Bright,
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.
2005,
Pubmed Bright,
Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States.
2006,
Pubmed Cady,
Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers.
2010,
Pubmed Cady,
Structure and function of the influenza A M2 proton channel.
2009,
Pubmed Cady,
Structure of amantadine-bound M2 transmembrane peptide of influenza A in lipid bilayers from magic-angle-spinning solid-state NMR: the role of Ser31 in amantadine binding.
2009,
Pubmed Camps,
Synthesis of several halobisnoradamantane derivatives and their reactivity through the S(RN)1 mechanism.
2001,
Pubmed Camps,
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.
2008,
Pubmed Chen,
Proton transport behavior through the influenza A M2 channel: insights from molecular simulation.
2007,
Pubmed Cui,
Molecular dynamics-solvated interaction energy studies of protein-protein interactions: the MP1-p14 scaffolding complex.
2008,
Pubmed Deyde,
Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide.
2007,
Pubmed Duff,
Neutron diffraction reveals the site of amantadine blockade in the influenza A M2 ion channel.
1994,
Pubmed Duque,
Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines.
2009,
Pubmed García Martínez,
Synthesis of substituted 1-norbornylamines with antiviral activity.
1995,
Pubmed Geluk,
Synthesis and antiviral properties of 1-adamantylguanidine. A modified method for preparing t-alkylguanidines.
1969,
Pubmed Grambas,
Maturation of influenza A virus hemagglutinin--estimates of the pH encountered during transport and its regulation by the M2 protein.
1992,
Pubmed Halgren,
MMFF VI. MMFF94s option for energy minimization studies.
1999,
Pubmed Hien,
Early pandemic influenza (2009 H1N1) in Ho Chi Minh City, Vietnam: a clinical virological and epidemiological analysis.
2010,
Pubmed Hornak,
Comparison of multiple Amber force fields and development of improved protein backbone parameters.
2006,
Pubmed Hu,
Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.
2010,
Pubmed Hu,
Histidines, heart of the hydrogen ion channel from influenza A virus: toward an understanding of conductance and proton selectivity.
2006,
Pubmed Inamoto,
Biologically active polycycloalkanes. 6. Antiviral 1-tricyclo[4.3.1.1 2,5]undecyl derivatives.
1979,
Pubmed Jing,
Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel.
2008,
Pubmed
,
Xenbase Khurana,
Computational study of drug binding to the membrane-bound tetrameric M2 peptide bundle from influenza A virus.
2011,
Pubmed Khurana,
Molecular dynamics calculations suggest a conduction mechanism for the M2 proton channel from influenza A virus.
2009,
Pubmed Kolocouris,
Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.
2008,
Pubmed Kolocouris,
Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
1994,
Pubmed Kolocouris,
Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
1996,
Pubmed Kolocouris,
Design and synthesis of bioactive adamantane spiro heterocycles.
2007,
Pubmed Lagoja,
Anti-influenza virus agents: synthesis and mode of action.
2008,
Pubmed Lamb,
Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface.
1985,
Pubmed Lundahl,
Synthesis and antiviral activities of adamantane spiro compounds. 1. Adamantane and analogous spiro-3'-pyrrolidines.
1972,
Pubmed Ma,
Identification of the pore-lining residues of the BM2 ion channel protein of influenza B virus.
2008,
Pubmed
,
Xenbase Mathur,
In vitro antiviral activity and preliminary clinical trials of a new adamantane compound.
1973,
Pubmed Morley,
Validation of an empirical RNA-ligand scoring function for fast flexible docking using Ribodock.
2004,
Pubmed Naïm,
Solvated interaction energy (SIE) for scoring protein-ligand binding affinities. 1. Exploring the parameter space.
2007,
Pubmed Ohigashi,
An amantadine-sensitive chimeric BM2 ion channel of influenza B virus has implications for the mechanism of drug inhibition.
2009,
Pubmed Pebody,
Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010.
2010,
Pubmed Pinto,
The M2 proton channels of influenza A and B viruses.
2006,
Pubmed Rosenberg,
Coexistence of two adamantane binding sites in the influenza A M2 ion channel.
2010,
Pubmed Saito,
Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2.
2003,
Pubmed Schnell,
Structure and mechanism of the M2 proton channel of influenza A virus.
2008,
Pubmed Scholtissek,
How to overcome resistance of influenza A viruses against adamantane derivatives.
1998,
Pubmed Setaki,
Synthesis, conformational characteristics and anti-influenza virus A activity of some 2-adamantylsubstituted azacycles.
2006,
Pubmed Skehel,
Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.
2000,
Pubmed Smit,
Synthesis and antiviral activities of adamantane spiro compounds. 2.
1972,
Pubmed Stamatiou,
Heterocyclic rimantadine analogues with antiviral activity.
2003,
Pubmed Stouffer,
Structural basis for the function and inhibition of an influenza virus proton channel.
2008,
Pubmed Stylianakis,
Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties.
2003,
Pubmed Tataridis,
Influence of an additional 2-amino substituent of the 1-aminoethyl pharmacophore group on the potency of rimantadine against influenza virus A.
2007,
Pubmed Tu,
Characterization of inhibition of M2 ion channel activity by BL-1743, an inhibitor of influenza A virus.
1996,
Pubmed
,
Xenbase Vanderlinden,
Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin.
2010,
Pubmed Wang,
Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus.
2009,
Pubmed
,
Xenbase Whitney,
Antiviral agents. I. Bicyclo [2.2.2] octan- and -oct-2-enamines.
1970,
Pubmed Yi,
A secondary gate as a mechanism for inhibition of the M2 proton channel by amantadine.
2008,
Pubmed Zarubaev,
Synthesis and anti-viral activity of azolo-adamantanes against influenza A virus.
2010,
Pubmed Zhirnov,
Solubilization of matrix protein M1/M from virions occurs at different pH for orthomyxo- and paramyxoviruses.
1990,
Pubmed Zoidis,
Are the 2-isomers of the drug rimantadine active anti-influenza A agents?
2003,
Pubmed Zoidis,
Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
2009,
Pubmed Zoidis,
Design and synthesis of bioactive 1,2-annulated adamantane derivatives.
2008,
Pubmed Zoidis,
Heterocyclic rimantadine analogues with antiviral activity.
2006,
Pubmed
